Sign up for free insights newsletter
Lupin Limited

Lupin Limited

LUPINNSE

Need professional-grade analysis? Visit stockanalysis.com

₹2,331.80
+0.40%
End of day
Market Cap

$1.08T

P/E Ratio

23.27

Employees

24,006

Dividend Yield

N/A

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino4.634.684.573.414.13
Calmar42.4713.7811.198.3213.69
Sharpe2.202.902.662.022.41
Omega1.611.521.471.371.45
Martin84.9338.6028.8320.8133.19
Ulcer1.111.601.741.791.67

Lupin Limited (LUPIN) Price Performance

Lupin Limited (LUPIN) trades on NSE in INR. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at INR2331.80, up 0.40% from the previous close.

Over the past year, LUPIN has traded between a low of INR1889.70 and a high of INR2357.30. The stock has gained 19.9% over this period. It is currently 23.4% above its 52-week low.

Lupin Limited has a market capitalization of $1.08T, with a price-to-earnings ratio of 23.27.

About Lupin Limited

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, women's health, and central nervous system areas, as well as pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies. In addition, it focuses on various therapeutic spectrum, including rheumatology, oncology, neuroscience, and renal therapies. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consists of labs and collection centers. The company has a strategic collaboration with TB Alliance for the development and commercialization of the investigational drug Telacebec for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Company Info

Exchange
NSE
Currency
INR
Country
India

Financial Metrics

Revenue (TTM)
$261.51B
EBITDA
$68.56B
Profit Margin
17.76%
EPS (TTM)
101.29
Book Value
429.87

Technical Indicators

52 Week High
₹2,377.60
52 Week Low
₹1,855.00
50 Day MA
₹2,216.07
200 Day MA
₹2,042.91
Beta
0.31

Valuation

Trailing P/E
23.27
Forward P/E
18.05
Price/Sales
4.12
Price/Book
5.46
Enterprise Value
$1.07T